CVS Pharmacy, the second-largest drug store chain in the United States, announced today that it will cease selling cigarettes in all its stores this year, citing the company's commitment to health care. CVS chief medical officer, Troyen Brennan, said in a statement that, "Stopping the sale of cigarettes and tobacco will make a significant difference in reducing the chronic illnesses associated with tobacco use."
There's no doubt that cigarettes are unhealthy -- and that second-hand smoke has exposed non-smokers to health risks as well. But CVS' decision doesn't affect second-hand smoke, and won't necessarily make a steep dent in overall smoking rates. Other chains, such as Target, haven't sold cigarettes in years.
Top 5 Healthcare Equipment Stocks To Buy Right Now: Waters Corp (WAT)
Waters Corporation (Waters), incorporated on December 6, 1991, is an analytical instrument manufacturer that primarily designs, manufactures, sells and services, through its Waters Division, high performance liquid chromatography (HPLC), ultra performance liquid chromatography (UPLC and together with HPLC, referred to as LC) and mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products and post-warranty service plans. These systems are complementary products that are frequently employed together (LC-MS) and sold as integrated instrument systems using a common software platform and are used along with other analytical instruments. Through its TA Division (TA), the Company primarily designs, manufactures, sells and services thermal analysis, rheometry and calorimetry instruments. The Company is also a developer and supplier of software-based products that interface with the Company's instruments and are typically purchased by customers as part of the instrument system. The Company's products are used by pharmaceutical, life science, biochemical, industrial, nutritional safety, environmental, academic and governmental customers working in research and development, quality assurance and other laboratory applications. The Company operates in two segments: Waters Division and TA Division.
In January 2012, the Company acquired Baehr Thermoanalyse GmbH. In July 2012, the Company acquired Blue Reference, Inc. During the year ended December 31, 2012, the Company introduced the Xevo G2-S Q-TofTM and Xevo G2-S Tof mass spectrometers, bringing StepWave ion technology to its bench-top time-of-flight mass spectrometers.
Waters Division
HPLC is used to identify and analyze the constituent components of a variety of chemicals and other materials. HPLC is used to identify new drugs, develop manufacturing methods and assure the potency and purity of new pharmaceuticals. HPLC is also used in a variety of other applica! tions, such as analyses of foods and beverages for nutritional labeling and compliance with safety regulations, the testing of water and air purity within the environmental testing industry, as well as applications in other industries, such as chemical and consumer products. HPLC is also used by universities, research institutions and governmental agencies, such as the United States Food and Drug Administration (FDA) and the United States Environmental Protection Agency (EPA). The ACQUITY UPLC I-Class provides a solution to a critical need by successfully analyzing compounds that are limited in amount or availability.
Waters manufactures LC instruments that are offered in configurations that allow for varying degrees of automation, from component configured systems for academic research applications to fully automated systems for regulated testing, and that have a variety of detection technologies, from ultra-violet (UV) absorbance to MS, optimized for certain analyses. The Company also manufactures tailored LC systems for the analysis of biologics, as well as an LC detector utilizing evaporative light scattering technology to expand the usage of LC to compounds.
The primary consumable products for LC are chromatography columns. These columns are packed with separation media used in the LC testing process and are replaced at regular intervals. The Company's chemistry consumable products also include environmental and nutritional safety testing products. Environmental laboratories use these products for quality control and proficiency testing and also purchase product support services required to help with their federal and state mandated accreditation requirements or with control over critical pharmaceutical analysis. In addition, the Company provides tests to identify and quantify mycotoxins in various agricultural commodities. These test kits provide reliable, quantitative detection of particular mycotoxins through the choice of flurometer, LC-MS or HPLC.
The Co! mpany off! ers a range of MS instrument systems utilizing various combinations of quadrupole, Tof, ion mobility and magnetic sector designs. These instrument systems are used in drug discovery and development, as well as for environmental, clinical and nutritional safety testing. The spectrometers sold by the Company are designed to utilize an LC system as the sample introduction device.
The Company�� smaller-sized mass spectrometers, such as the single quadrupole detector (SQD) and the tandem quadrupole detector (TQD), referred to as LC detectors and are sold as part of an LC system or as an LC system upgrade. Quadrupole systems, such as the Xevo TQ and Xevo TQ-S instruments, are used for late-stage drug development, including clinical trial testing. Quadrupole time-of-flight (Q-Tof) instruments, such as the Company�� SYNAPT G2-S, are used to analyze the role of proteins in disease processes, an application referred to as proteomics. Its SYNAPT G2 HDMS and SYNAPT G2 MS systems are exact mass MS/MS platforms. The Company�� Xevo TQ-S instrument system is designed for UPLC/MS/MS applications. Its Xevo G2 Q-Tof is exact mass quantitative and qualitative bench-top MS/MS instrument systems. The Company�� SYNAPT G2-S incorporates Waters StepWave ion transfer optics and Triwave ion mobility technologies along with a range of informatics tools.
TA Division
Thermal analysis measures the physical characteristics of materials as a function of temperature. Rheometry instruments complement thermal analyzers in characterizing materials. Rheometry characterizes the flow properties of materials and measures their viscosity, elasticity and deformation under different types of loading or other conditions.
Thermal analysis measures the physical characteristics of materials as a function of temperature. Rheometry instruments complement thermal analyzers in characterizing materials. Rheometry characterizes the flow properties of materials and measures their viscosity, elast! icity and! deformation under different types of loading or conditions. As with systems offered through the Waters Division, a range of instrumental configurations is available with sample handling and information processing automation. In addition, systems and accompanying software packages can be tailored for specific applications. The Company�� Q-Series family of differential scanning calorimeters includes a range of instruments, from analyzers to systems, which can accommodate robotic sample handlers and a range of sample cells and temperature control features for analyzing a range of materials.
The Company competes with Agilent Technologies, Inc., Shimadzu Corporation, Bruker Corporation, Danaher Corporation, Thermo Fisher Scientific Inc, PerkinElmer, Inc., Mettler-Toledo International Inc., NETZSCH-Geraetebau GmbH, Thermo Fisher Scientific Inc., Malvern Instruments Ltd., Anton-Paar, Phenomenex, Inc., Supelco, Inc., Merck and Co., Inc. and General Electric Company.
Advisors' Opinion:- [By Geoff Gannon] strong>Balchem (BCPC)
路 Idexx (IDXX)
路 II-VI (IIVI)
路 Mesa Laboratories (MLAB)
路 Masimo (MASI)
I don�� know most of those companies very well. I probably know Waters the best out of that group.
Obviously, there are companies outside of Phil Fisher�� area of focus ��manufacturing with technical elements ��that fit many of his principles.
Among really high profile companies, the three that stand out are:
1. Amazon (AMZN)
2. Netflix (NFLX)
3. Wells Fargo (WFC)
Of those 3, Amazon stands out the most. Jeff Bezos often seems to be channeling Phil Fisher. And I imagine that if Fisher were ever interested in a retailer it would be a retailer with Amazon�� attitude about technology, customers, growth, and the long-term. More than anything though it�� Amazon�� constant internal push to develop new sales and especially new ways to serve existing customers without being prompted by outside forces that makes me think it�� a company Phil Fisher would be very interested in.
Fisher liked companies that had a philosophy of growth. Something internal to the organization that caused it to seek ways to grow sales, win new customers, develop new products. Fisher obviously wanted a great organization in an industry with great long-term prospects. But I think a lot of growth investors focus more on the latter issue than Fisher would. I know they don�� focus enough on the first issue. Fisher wanted a great organization first and foremost.
I�� not sure any of the stocks I��e mentioned in this article are necessarily good buys. The one exception is Wells Fargo. I�� never comfortable calling a bank entirely safe. So I�� less sure about suggesting any financial stock as a good buy than I am about stocks in most industries. But if you look at what Wells Fargo has achieved and what they are likely to achieve over the next ten years or so and then consider the price you are paying f
- [By Teresa Rivas]
Danaher (DHR) and Waters Corporation (WAT) were mirror images of one another, with the former rising 1.3% at recent check and the latter falling by 1.3%.
Top 10 Medical Companies To Watch For 2014: Elan Corporation PLC (ELN)
Elan Corporation, plc (Elan), incorporated in December 1969, is a neuroscience-based biotechnology company. The Company is focused on discovering and developing advanced therapies in neurodegenerative and autoimmune diseases. Elan�� business focuses on neurodegenerative diseases, such as Alzheimer�� disease and Parkinson�� disease; autoimmune diseases, including MS and Crohn�� disease and neo-epitope based targets for treatments across a range of therapeutic indications. Tysabri is a treatment for MS and Crohn�� disease that the Company markets and distributes with Biogen Idec. On September 16, 2011, Elan sold its EDT business to Alkermes, Inc. In November 2011, Elan launched a collaboration with the University of Cambridge, England, the Cambridge-Elan Centre for Research Innovation and Drug Discovery (Cambridge-Elan Centre). On December 21, 2012, the Company completed the demerger of Prothena Corporation plc. In April 2013, it closed the TYSABRI (natalizumab) Collaboration Transaction with Biogen Idec.
Tysabri
Tysabri, which is an alpha-4 integrin inhibitor, is a therapy for MS, a neurological disorder involving central nervous system dysfunction among adults. Tysabri is approved in more than 65 countries. Tysabri is approved in the United States as a monotherapy for relapsing forms of MS, for patients who have had an inadequate response to, or are unable to tolerate, an alternative MS therapy. In the European Union, it is approved for relapsing-remitting MS (RRMS) in adult patients who have failed to respond to beta interferon or have rapidly evolving, severe RRMS. As of December 31, 2011, there were approximately 64,400 patients on Tysabri therapy worldwide.
In June 2011, the European Commission (EC) approved the inclusion of the anti-JCV antibody status as an additional factor in stratifying patients at risk for developing PML in the Summary of Product Characteristics��(SmPC) for Tysabri in the European Union. The Company has developed a two-step ! enzyme-linked immunosorbent assay (ELISA), STRATIFY JCV, with Biogen Idec. The assay detects anti-JCV antibodies in the blood of patients, and is commercially available in Europe. In January 2012, the FDA cleared the assay for commercial use in the United States. As of December 31, 2011, over 80,000 tests had been administered using the assay. Tysabri is marketed and distributed by Elan and Biogen Idec. The Company�� research group, Neotope, is focused on creating monoclonal antibodies based on neo-epitope targets for the treatment of a range of therapeutic indications.
Beta Amyloid Immunotherapies (AIP)
Beta amyloid immunotherapy includes the treatment of Alzheimer�� disease by inducing or enhancing the body�� immune response in order to clear toxic species of beta amyloid from the brain. The AIP includes bapineuzumab (intravenous and subcutaneous delivery) and ACC-001, as well as other compounds. Bapineuzumab is an experimental humanized monoclonal antibody delivered intravenously that is being studied as a treatment for mild to moderate Alzheimer�� disease. It is designed to provide antibodies to beta amyloid directly to the patient (passive immunotherapy).
ELND005, an A� Aggregation Inhibitor
The small molecule ELND005 (Scyllo-inositol) is a beta amyloid anti-aggregation agent. Preclinical data suggest that ELND005 may act through the mechanism of preventing and reversing the fibrilisation of beta amyloid (the aggregation of beta amyloid into clumps of insoluble oligomers). ELND005 may have additional applications in psychiatric indications, such as bipolar disorder. In November 2011, the Company entered into a manufacturing agreement for the supply of the active pharmaceutical ingredient for ELND005 with Lonza Group AG.
Neotope Biosciences Limited
Neotope Biosciences Limited (Neotope) is the Company�� wholly owned subsidiary that focuses on the discovery and development of antibodies to neo-epitope related targ! ets for t! he treatment of a range of indications. It includes amyloidosis, diabetes, cancer and macular degeneration. Neotope�� portfolio of targets includes alpha-synuclein for the potential treatment of synucleinopathies, such as Lewy body dementia and Parkinson�� disease, tau for Alzheimer�� disease and other tauopathies. It also has a program for type 2-diabetes.
Onclave Therapeutics Limited
Elan�� wholly owned subsidiary Onclave Therapeutics Limited (Onclave) was formed to develop assets originating from Elan that have application in oncology related diseases. Onclave�� program, NEOD001, which originated from Neotope, is being investigated for the treatment of AL amyloidosis, which is a fatal disease involving abnormal accumulation of amyloid in organs and tissue. During the year ended December 31, 2011, Onclave filed for orphan drug designation of NEOD001. Onclave�� pipeline includes additional compounds with relevance in diverse cancer indications.
The Company competes with Biogen Idec, Bayer Schering Pharma AG, Bayer Schering Pharma, Merck Serono, Pfizer, Teva Neurosciences, Inc., Sanofi-Aventis and Novartis AG.
Advisors' Opinion:- [By John Maxfield]
Of the dozens of trades alleged in the various documents, the one that best demonstrates this is SAC's bet on the pharmaceutical giant Elan (NYSE: ELN ) in anticipation of the latter's Phase II trial results for a drug to treat Alzheimer's disease. I've mapped out the trade in the chart below.
- [By Sean Williams]
Elan (NYSE: ELN )
Having a lot of cash in the biotech sector doesn't mean that a company's clinical trials will translate into success. Elan's claim to fame was the development of multiple sclerosis drug Tysabri, which it licensed out to Biogen Idec (NASDAQ: BIIB ) . Sales of the drug hit $1.6 billion last year. - [By Brian Orelli]
Most recently Elan (NYSE: ELN ) spun out its drug discovery business into Prothena. Without the burden of a drug discovery unit, the parent company is now being pursued by Royalty Pharma, although Elan isn't keen on its current offer.
Top 10 Medical Companies To Watch For 2014: Atossa Genetics Inc (ATOS)
Atossa Genetics Inc., incorporated on April 30, 2009, is a development-stage healthcare company focused on the prevention of breast cancer through the commercialization of diagnostic tests that can detect precursors to breast cancer, and through the research, development, and ultimate commercialization of treatments for pre-cancerous lesions. The Company�� diagnostic tests consist of medical devices cleared by the Food and Drug Administration (FDA), which can collect fluid samples from the breast milk ducts, where over 95% of breast cancers arise. During the fiscal year ended September 30, 2012, the tests that the Company offered and that are in development consist of ForeCYTE, ArgusCYTE, FullCYTE and NextCYTE. In September 2012, the Company acquired all of the assets of Acueity.
The ForeCYTE Breast Health Test provides personalized information about the 10-year and lifetime risk of breast cancer for women between ages 18 and 73. The ArgusCYTE Breast Health Test provides information to help inform breast cancer treatment options and to help monitor potential recurrence. The FullCYTE Breast Health Test is designed to assess the individual breast ducts for pre-cancerous changes in women previously identified to be at high risk for breast cancer. The NextCYTE Breast Cancer Test is designed to profile breast cancer specimens for prediction of treatment outcomes and distant recurrence in women newly diagnosed with breast cancer. MASCT, Oxy-MASCT, and its name and logo are the trademarks. ForeCYTE, FullCYTE, NextCYTE, and ArgusCYTE are its service marks.
Advisors' Opinion:- [By Virginia Harrison]
The other big Olympic sponsors are Visa (V, Fortune 500), Samsung (SSNLF), Panasonic (PCRFF), General Electric (GE, Fortune 500), Dow Chemical (DOW, Fortune 500), Procter & Gamble (PG, Fortune 500), Omega (OCFN) and Atos (ATOS). They're staying tight-lipped about the issue in public but a senior official at the International Olympic Committee said this month that several had raised concerns about how the law could affect the Games.
- [By Rebecca McClay]
Atossa Genetics Inc. (Nasdaq: ATOS) shares are up about 6% in midday trading due to a cancer breakthrough it plans to showcase this weekend...
Atossa will exhibit its ForeCYTE Breast Health Test at the 2013 Breast Cancer Symposium in San Francisco, CA, which starts Saturday.
Top 10 Medical Companies To Watch For 2014: Sonova Holding AG (SOON)
Sonova Holding AG is a Switzerland-based company operating in the healthcare sector. The Company, along with its subsidiaries, specializes in the design, development, manufacture, worldwide distribution and service of technologically advanced hearing systems for adults and children with hearing impairment. The Company is active in two operating segments: the Hearing instruments segment includes the companies that are active in the design, development, manufacture, distribution and service of hearing instruments and related products, and the Cochlear implants segment includes the companies that are active in the design, development, manufacture, distribution and service of hearing implants and related products. The Company operates worldwide and distributes its products in over 90 countries through its own distribution network and through independent distributors. Sonova Holding AG is the holding company of the Sonova Group. Advisors' Opinion:- [By Sofia Horta e Costa]
ThyssenKrupp AG slid to a 10-week low after raising 882.3 million euros ($1.2 billion) through a share sale. Antofagasta Plc led a measure of mining companies to a seven-week low. Sonova Holding AG (SOON) declined 1.5 percent as Morgan Stanley cut its rating on the Swiss hearing-aid maker. Orange SA slipped 3.4 percent amid concern a price war in the French mobile market will extend to fourth-generation data services.
- [By Corinne Gretler]
Sonova (SOON) advanced 6.9 percent to 126.50 Swiss francs after predicting that annual earnings before interest, taxes and amortization would grow as much as 14 percent, compared with a previous forecast of 9 percent to 13 percent. Sales will increase 8 percent to 10 percent, up from an earlier projection of 6 percent to 8 percent.
Top 10 Medical Companies To Watch For 2014: Alpha Pro Tech Ltd (APT)
ALPHA PRO TECH, LTD. (Alpha Pro Tech), incorporated on June 15, 1994, is in the business of protecting people, products and environments. The Company also manufactures a line of building supply construction weatherization products through its wholly-owned subsidiary, Alpha ProTech Engineered Products, Inc. Its products are sold under the Alpha Pro Tech brand name, as well as under private label. The Company's products are grouped into three business segments: the Building Supply segment, which consists of construction weatherization products, such as housewrap and synthetic roof underlayment, the Disposable Protective Apparel segment, which consists of disposable protective apparel, such as shoecovers, bouffant caps, gowns, coveralls, lab coats, frocks and other miscellaneous products and the Infection Control segment, which consists of face masks and eye shields.
Building Supply
The Building Supply segment consists of a line of construction supply weatherization products, namely housewrap and synthetic roof underlayment. This line of products is a natural extension of the Company's core capabilities: creating products designed to protect people and environments. The housewrap, under the trademark REX, offers a weather resistant barrier and, to the homeowner, years of lower energy consumption. REX Wrap and REX Wrap Plus are woven and coated polypropylene micro perforated weather resistant barriers, and REX Wrap Fortis is an engineered composite made up of a woven fabric, a monolithic breather film and a non-woven sheet, offering a non-perforated membrane.
Disposable Protective Apparel
The Disposable Protective Apparel segment includes many different styles of disposable products, such as shoecovers, bouffant caps, gowns, coveralls, lab coats, frocks and other miscellaneous products. The products are manufactured by subcontractors in Asia and, to a much lesser extent, a subcontractor in Mexico. Certain products are made using materials supplied by th! e Company.
Infection Control
The Infection Control segment includes face masks and eye shields. The Company's face masks come in a range of filtration efficiencies and styles. The Company's Positive Facial Locka feature provides a custom fit to the face to prevent blow-by for better protection. The Company's Magic Arch feature holds the mask away from the nose and mouth, creating a comfortable breathing chamber.
Kimberly Clark, 3M Company, Johnson & Johnson, White Knight/Precept, Cardinal Health, Inc., Medline Industries Inc., VWR International, LLC, Kimberly Clark, 3M Company, Kappler USA, DuPont and Allegiance Health Care.
Advisors' Opinion:- [By Cindy Bowser]
Alpha Pro Tech (APT) is a Delaware corporation headquartered in Ontario. APT was our ��ompany of the Month��feature in August 2000 at $1.31 per share.
Top 10 Medical Companies To Watch For 2014: Hemispherx Biopharma Inc (HEB)
Hemispherx Biopharma, Inc. (Hemispherx) is a specialty pharmaceutical company engaged in the clinical development of new drugs therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders. Hemispherx focuses on two core pharmaceutical technology platforms Ampligen and Alferon N Injection.The commercial focus for Ampligen includes application as a treatment for Chronic Fatigue Syndrome (CFS) and as an influenza vaccine enhancer (adjuvant) for both therapeutic and preventative vaccine development. Alferon N Injection is a United States Food and Drug Administration (FDA) approved product with an indication for refractory or recurring genital warts. Alferon LDO (Low Dose Oral) is a formulation under development targeting influenza. It has three subsidiaries BioPro Corp., BioAegean Corp., and Core BioTech Corp. The Company's foreign subsidiary is Hemispherx Biopharma Europe N.V./S.A.
Ampligen
Ampligen is an experimental drug, which is undergoing clinical development for the treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). Over 1,000 patients have participated in the Ampligen clinical trials representing the administration of more than 90,000 doses of this drug. The Company is also engaged in ongoing, experimental studies assessing the efficacy of Ampligen against influenza viruses.
Alferon N Injection
Alferon N Injection is the registered trademark for the Company's injectable formulation of natural alpha interferon. Interferons are a group of proteins produced and secreted by cells to combat diseases. The Company's natural alpha interferon is produced from human white blood cells. Alferon N Injection [Interferon alfa-n3 (human leukocyte derived)] is a highly purified, natural-source, glycosylated, multi-species alpha interferon product.
Alferon LDO (Low Dose Oral)
Alferon LDO [Low Dose Oral Interferon Alfa-n3 (Human Leukocyte Derived)]! is an experimental low-dose, oral liquid formulation of Natural Alpha Interferon and like Alferon N Injection should not cause antibody formation, which is a problem with recombinant interferon. It is an experimental immunotherapeutic that works by stimulating an immune cascade response in the cells of the mouth and throat, enabling it to bolster systemic immune response through the entire body by absorption through the oral mucosa.
The Company competes with Pfizer, GlaxoSmithKline, Merck, AstraZeneca, Baxter International, Fletcher/CSI, AVANT Immunotherapeutics, AVI BioPharma and Genta.
Advisors' Opinion:- [By MONEYMORNING]
Hemispherix Biopharma Inc. (NYSE: HEB) is a specialty pharmaceutical company. It engages in the clinical development of new drug therapies based on natural immune system enhancing technologies and targets the treatment of viral and immune-based clinical disorders. The Philadelphia, Pa.-headquartered company gained widespread attention over the last several months for its work on flu research. Its flagship products include Alferon N Injection, approved by the FDA for a category of sexually transmitted disease infection. Experimental treatments include Ampligen and Oragens, in development stages for the potential treatment of global viral diseases and disorders of the immune system including human papilloma virus, human immunodeficiency virus, chronic fatigue syndrome, hepatitis, and influenza. Shares have traded as low as $0.18 and as high as $0.55 over the last year. At last check, shares were changing hands around $0.50 on volume of 2 million shares.
Top 10 Medical Companies To Watch For 2014: Cytomedix Inc (CMXI)
Cytomedix, Inc. (Cytomedix), incorporated in April 29, 1998, is a regenerative therapies company marketing and developing products within the United States and internationally .The Company commercializes cell-based technologies that harness the regenerative capacity of the human body to trigger natural healing. The Company is a commercial operation, and a robust clinical pipeline representing a logical extension of its commercial technologies in the evolving field of regenerative medicine. Cytomedix primarily operates in the United States. Its commercial offerings are centered on its point of care platform technologies for the safe and efficient separation of blood and bone marrow to produce platelet based therapies or cell concentrates.
The Company markets and selsl two distinct platelet rich plasma (PRP) technologies, the AutoloGel System for wound care and the Angel concentrated Platelet Rich Plasma (cPRP) Sytem in orthopedic and cardiovascular markets. Its clinical pipeline includes the ALDH, which are cell-based therapies (Bright Cells). In February 2012, the Company acquired Aldagen, Inc.
The AutoloGel System
The AutoloGel System is a point of care device for the production of a platelet based bioactive therapy derived from a small sample of the patient�� own blood. Using the patient�� own platelets as a therapeutic agent, AutoloGel harnesses the body�� natural healing processes to deliver growth factors, chemokines and cytokines known to promote angiogenesis and to regulate cell growth and the formation of new tissue.
Angel Product Line
The Angel concentrated Platelet Rich Plasma (cPRP) System is a multi-functional cell separation device which produces concentrated platelet rich plasma for use in the operating room and clinic and is used in a range of orthopedic and cardiovascular indications. Similar to the AutoloGel System, the Angel System is a point of care device for the production of a concentrated, aseptic platelet! -based bioactive therapy derived from a small sample of the patient�� own blood. The resulting cPRP is applied at the site of injury to promote healing. The Angel product line also includes ancillary products such as phlebotomy and applicator supplies and activAT. activAT is designed to produce autologous thrombin serum from platelet poor plasma and is sold exclusively in Europe and Canada, where it provides a safe alternative to bovine-derived products.
ALDHbr Cell Technology and Development Pipeline
The ALDHbr (Bright Cell) technology is an approach to cell-based regenerative medicine and a logical extension of its commercial technologies in the evolving regenerative medicine market, with potential clinical indications in markets with unmet medical needs such as peripheral arterial disease and ischemic stroke. The Bright Cell technology is in that it utilizes an intracellular enzyme marker to facilitate fractionation of essential regenerative cells from a patient�� bone marrow. The bone marrow fractionation process identifies and isolates active stem and progenitor cells expressing high levels of the enzyme aldehyde dehydrogenase, or ALDH, which is a key enzyme involved in the regulation of gene activities associated with cell proliferation and differentiation.
The Company�� lead product candidate, ALD-401, is an autologous preparation of Bright Cells for the post-acute treatment of ischemic stroke. ALD-401 is being evaluated in the RECOVER-Stroke clinical study, an ongoing 100-patient, double-blind, placebo-controlled Phase 2 study in patients with unilateral, cerebral ischemic stroke with an NIH stroke scale score of less than 22. An additional product candidate, ALD-301, is in clinical development for peripheral arterial disease (PAD), a condition causing reduced flow of blood and oxygen to muscles in the leg. It has completed a Phase 1/2 study of autologous ALD-301 in critical limb ischemia (CLI), a late stage condition caused by PAD. The Phase 2 PACE! (Patient! s with Intermittent Claudication Injected with ALDH Bright Cells) study is an 80 patient, double-blind, placebo-controlled clinical trial intended to demonstrate the safety and efficacy of ALD-301 (Bright Cells) in patients diagnosed with IC.
The Company competes with Harvest Technologies (a subsidiary of Terumo), Biomet, Arteriocyte, and Arthrex.
Advisors' Opinion:- [By James E. Brumley]
To give credit where it's due, Cytomedix, Inc. (OTCBB:CMXI) and Baxter International Inc. (NYSE:BAX) have both helped shape the landscape of the hemostasis (bleeding control) market with their products, AutoloGel and TISSELL, respectively. Arch Therapeutics Inc. (OTCBB:ARTH) has proverbially taken their concepts "up a notch", however, and its direct solution to a problem that CMXI and BAX can't quite solve may make ARTH the hottest trading candidate in the hemostasis space.
- [By Bryan Murphy]
When traders think of post-surgical wound management stocks, they may first think of names like Cytomedix, Inc. (OTCBB:CMXI) or Alliqua Inc. (OTCMKTS:ALQA). And well they should. Both companies have something of a history in the arena. ALQA is the purveyor of SilverSeal and Hydress antibiotic bandages, while CMXI is the developer of the AutoloGel system, which induces an affected patient's on body to do what it's supposed to do if there's a wound that won't heal. Cytomedix also makes the Angel platelet-rich plasma (PRP) delivery system. There's a relatively new name to add to the list of game-changing stocks in wound-management industry, however.... Arch Therapeutics Inc. (OTCBB:ARTH). The company is developing - well, has developed - a product called AC5 that nips post-surgical bleeding in the bud, largely negating the need for other post-surgical bleeding-control measures.
No comments:
Post a Comment